Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

27.20USD
19 Jan 2018
Change (% chg)

$2.20 (+8.80%)
Prev Close
$25.00
Open
$28.65
Day's High
$28.80
Day's Low
$26.65
Volume
805,671
Avg. Vol
208,813
52-wk High
$33.00
52-wk Low
$13.65

Select another date:

Fri, Jan 5 2018

Acorda Therapeutics exploring sale: WSJ

Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

UPDATE 3-Acorda Therapeutics scraps Parkinson's drug after deaths

* Last week company reported five deaths in tozadenant studies

Acorda Therapeutics scraps Parkinson's drug after deaths

Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.

Acorda Therapeutics scraps development of Parkinson's disease drug

Nov 20 Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

UPDATE 4-Acorda reports five deaths in Parkinson's trial, shares plunge

* Shares tank nearly 40 pct (Recasts, adds CEO and analyst comments, updates shares)

BRIEF-Acorda provides update on tozadenant development program

* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death​

Select another date: